Patent cliffs & loss of exclusivity
BridgeBio Pharma is a commercial-stage, multi-product biopharmaceutical company in Palo Alto, California, listed on Nasdaq as BBIO. In its own words it "exists to develop transformative medicines for genetic conditions", and it describes itself as "organized around a portfolio operating model to discover, develop, and deliver medicines for patients with genetic diseases". It was founded in 2015 by Neil Kumar, who is chief executive. Two businesses have been spun out of it, BridgeBio Oncology Therapeutics and GondolaBio, in both of which it retains a minority equity interest.
| AngelList URL | https://angel.co/company/bridgebio |
|---|---|
| Business Model | Commerce |
| CAGE Code | 8FVJ9 |
| Legal Name | BridgeBio Pharma, Inc. |
| Company Operating Status | Active |
| Crunchbase URL | https://www.crunchbase.com/organization/bridgebio |
| Email format | {first}.{last} |
| Facebook URL | https://www.facebook.com/BridgeBio-Pharma-100543364785856/ |
Loss-of-exclusivity dates are derived from the FDA Orange & Purple Books; company detail is from the CliffBio graph. Estimates are projections, not legal advice.